thereal_rok (@thereal_rok) header
thereal_rok (@thereal_rok) profile picture

Precisely track market trends. Receive daily pre-market analysis, a curated selection of three hot stocks, and real-time trading updates. Take control of your i

USA
Joined June 2011
Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)Photo by thereal_rok (@thereal_rok)
$HTZ saw this on Reddit . Take with a grain of salt- I know this is a “trust me bro” source but seems very specific. If true, the bearish narrative around this stock will be destroyed
3
1
12
817
$GRRR Okay, I read the transcript. It looks like they will be okay. They've already sealed a tier 1 investment bank and an anchor investor for the $1.7 billion dollars to finance Yotta 1 and Yotta 2. This is important, as it will reduce the need to further dilute shareholder value. Jay said they are repaying the interest on the convertible bonds with cash and not shares. I see what they are doing. I believe there will be minimal dilution if Jay and Bruce executes this correctly. Yotta 1 will become operational by January 2027. 6 million per month in revenue will start accruing. Yotta 2 will come shortly after with more revenues coming in.
4
1
38
1,775
$SPCX MS based this on each Starship carrying 50 Starlink V3 satellites, with each satellite generating ~$8 million in annualized revenue. Five year target of $1,640/share with a daily launch cadence.
1
107
🚨 $SLS BULLS — THE REGAL FINAL ANALYSIS COULD REVEAL SOMETHING HUGE! 🔥🚀 One of the most intriguing pieces of the REGAL story is EXTENDED GPS DOSING! If the extended dosing protocol began in 2025, could it help explain why the GPS survival curves continued separating from BAT? Think about it! GPS is designed to train the immune system to recognize and attack leukemia cells. Continued dosing could potentially sustain that immune response and improve long-term survival! Now imagine the final Kaplan-Meier curves showing increasing separation over time, with additional analyses suggesting patients benefited from prolonged treatment! It could raise exciting questions about how much more effective GPS might be with optimized long-term dosing! The key will be separating treatment effects from differences in which patients remained eligible for dosing. REGAL’s topline results may have been just the beginning. The detailed data could tell an even BIGGER story! 🚀
3
335
$NBIS Based on Nebius November 12 guidance, the target for pre-tax breakeven is Q4 2027, and that’s management’s own target, not just an analyst’s. Q1 and Q2 2027 are the first big checkpoints. If revenue and margins track properly then, confidence in the Q4 2027 break-even target gets stronger. So, you can watch for execution signs in the first half of 2027, rather than waiting for the official breakeven date !
1
130
$CAPR waiting Till real price Like 😂:
2
332
$HELP The incentive structure is not alligned with shareholders. It’s public info that can be found on their site under the investor tab
3
364
$GRRR Maybe it's a good thing our expectations are at a all time low. Jay has alot of explaining to do. No hidden secret, data centers will cost alot. We don't need to hear vendor financing is in final stages and will be announced the "coming days" this is horseshit. We need factual updates. Specifics on Yotta 1 and progression on Yotta 2. Goodluck to us
1
9
2,295
$EOSE Data center electricity use could double by 2030, IEA says Data center electricity use could double to about 1,000 terawatt-hours a year by 2030 under the IEA’s Stated Policies Scenario. Grid spending rises 75% over the next decade in the IEA’s Current Policies Scenario, making power networks a major energy investment theme.
1
533
$CRWV Original coreweave concerns that CNBC talked about every day two clients are the majority of their backlog what happens if they fail...I guess not ..much larger than anyone dreamed Chips would depreciate faster than the books showed and cause massive losses...I guess not ..old chips selling for more than when purchased Too many data centers compute prices would be commoditized..I guess not they have 2x-3x and they have 132B TAKE OR PAY Nividia circular deals..the only deal that Nividia has with them is a 5-6 year deal to buy excess compute if there is any....and there is none Concerns about hyperscalers competing with them...somewhat..but coreweave continues to win industry awards and demand is accleration because of anthropic and open ai and with permits slowing compute prices will go higher as demand outstrips capacity for years to come.
1
134
$CRMD CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says PUBLISHED : NOVEMBER 16, 2026 Ref: Fidelity Oppenheimer expects CorMedix’s DefenCath and Rezzayo, along with its recent Heron Therapeutics acquisition, to drive 2027 growth, according to Fidelity. The brokerage anticipates a DefenCath reset in the second quarter of 2027, followed by pricing recovery and improvement through the fourth quarter. Medicare Advantage contracting terms should support more durable DefenCath economics after the add-on period expires in 2029. The FDA is expected to decide in the first quarter on Rezzayo’s supplemental new drug application for preventing invasive fungal diseases; priority review has been granted. Approval could lead to a launch around mid-2027. Heron could add $112 million to 2027 sales.
1
153
$VKTX KLRA has a very good drug but not a great one. What would you expect a CEO to say when his drug lacks the half life to support monthly dosing? VK2735 appears to be a great drug with much more potential ways to generate revenue than Ribupatide. A silver tongued CEO is a double edged sword. VK2735 is BIC 👇👇👇👇
3
2
1
28
5,857
A dedicated WhatsApp group for $VKTX holders is now online! All investors holding $VKTX stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join: stockswhatsapp.app/9UOw3k Our assistant Jennifer is available to assist you anytime!
33
$CLOV all you need to know
1
1
11
778
$POET If wafer and component availability are indeed so bottlenecked, Poet having ~750M in cash and having already secured wafer capacity isn’t a small thing. A lot of photonic startups exist who will take a back seat due to input unavailability. Starting to think Lumilens needed Poet for more than just the tech. Poet has manufacturing facilities and supplies that Lumilens would be hard pressed to acquire otherwise.
2
2
13
903
$CLOV linkedin confirmation of counterpart use in Mississippi Largest health centre in the state by the way...
2
8
673
A dedicated WhatsApp group for $CLOV holders is now online! All investors holding $CLOV stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join: stockswhatsapp.app/9UOw3k Our assistant Jennifer is available to assist you anytime!
36
$INO Excellent Presentation: Delivering on the Promise of DNA Medicine.
1
173
$PLUG Plenty of upside potential with little downside risk as we move into this quarter’s positive EBITDA and 2027’s positive operating income.
1
5
585
$NWBO It was a battle yesterdsy. Above average volume of 6.3 million. Nice close above 0.15. It is absolutely obvious, the desperation to keep the price from rising. The shorts must have a very high count of FTDs , behaving this way. Who in the world would still try to short a 15 cents stock for a financial gain? They need hiiiiiigh volume days, 100 million days on to cover. That’s why they keep it low. The amount of shares shorted must be gigantic. Why else this strategy and struggle at 15 cents. This will have huge moves. Big Pharma had paid tens of billions for a chance in proof of concept. DCVAX is effective, safe and now scalable, applicable to potentially all cancers, trials speak the results, combos speak the results, brain power talent is joining the team, manufacturing cooperation with government run organizations, and this trades below 300 million market cap. Just keep buying with your lunch money. If you don’t see it, stop investing anywhere . This is beyond obvious
7
557
$NIO Regarding the issue of buying a used EV even before the battery warranty expires: What matters is how much warranty will remain during the years you expect to own the car. If you buy a five-year-old Tesla and plan to keep it for six years, you’re already choosing to own it for at least three years beyond the original eight-year battery warranty. A high-mileage car could reach the mileage limit even sooner. That also sharpens the resale point. Even if you plan to sell when the car turns seven, your next buyer will see at most one year of battery coverage left. Buyers have a reason to factor that into their offers before the warranty expires. How large a discount the market will demand is still an open question. I think we’ll see these issues. Factor into resale prices going forward as EVs age out.
2
266